Gut-derived metabolites as treatment targets in chronic kidney disease-an avenue toward personalized medicine

被引：0
|
作者：
Holle, Johannes [1 ,2 ,3 ,4 ,5 ]
Bartolomaeus, Hendrik [4 ,5 ,6 ]
机构：
[1] Charite Univ Med Berlin, Dept Pediat Gastroenterol Nephrol & Metab Dis, Berlin, Germany
[2] Charite Univ Med Berlin, Expt & Clin Res Ctr, Berlin, Germany
[3] Max Delbruck Ctr Mol Med, Berlin, Germany
[4] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany
[5] Max Delbruck Ctr Mol Med Helmholtz Assoc, Berlin, Germany
[6] Univ Hosp Wurzburg, Inst Expt Biomed, Wurzburg, Germany
来源：
PEDIATRIC NEPHROLOGY | 2025年
关键词：
INDOXYL SULFATE; MICROBIOTA; CHILDREN;
D O I：
10.1007/s00467-024-06609-w
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：1505 / 1510
页数：6
相关论文
共 50 条
  • [41] Healthcare Data for Achieving a More Personalized Treatment of Chronic Kidney Disease
    Herrera-Gomez, Francisco
    Alvarez, F. Javier
    BIOMEDICINES, 2021, 9 (05)
  • [42] Co-toxicity of Endotoxin and Indoxyl Sulfate, Gut-Derived Bacterial Metabolites, to Vascular Endothelial Cells in Coronary Arterial Disease Accompanied by Gut Dysbiosis
    Choroszy, Marcin
    Sobieszczanska, Beata
    Litwinowicz, Kamil
    Laczmanski, Lukasz
    Chmielarz, Mateusz
    Walczuk, Urszula
    Roleder, Tomasz
    Radziejewska, Jadwiga
    Wawrzynska, Magdalena
    NUTRIENTS, 2022, 14 (03)
  • [43] The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease
    Zand, Ladan
    Kumar, Rajiv
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2017, 46 (04) : 983 - +
  • [44] Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease
    Koshida, Takeo
    Gohda, Tomohito
    Sugimoto, Takuya
    Asahara, Takashi
    Asao, Rin
    Ohsawa, Isao
    Gotoh, Hiromichi
    Murakoshi, Maki
    Suzuki, Yusuke
    Yamashiro, Yuichiro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [45] Dietary strategies for gut-derived protein-bound uremic toxins and cardio-metabolic risk factors in chronic kidney disease: A focus on dietary fibers
    Melekoglu, Ebru
    Samur, F. Gulhan
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2023, 63 (19) : 3994 - 4008
  • [46] Treatment choices and targets in Type 2 diabetes and chronic kidney disease
    Lomova-Williams, L.
    Mallipedhi, A.
    Benjamin, S.
    Price, D. E.
    Stephens, J. W.
    DIABETIC MEDICINE, 2013, 30 : 162 - 162
  • [47] Role of IL28B for chronic hepatitis C treatment toward personalized medicine
    Matsuura, Kentaro
    Watanabe, Tsunamasa
    Tanaka, Yasuhito
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (02) : 241 - 249
  • [48] CHRONIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES: NEW TARGETS OF MEDICINE ACTION
    Trubitsyna, Natalia P.
    Zaitseva, Natalia, V
    Severina, Anastasia S.
    Shamkhalova, Minara S.
    DIABETES MELLITUS, 2022, 25 (05): : 492 - 498
  • [49] LACTOBACILLUS RHAMNOSUS L34, DERIVED FROM THAI POPULATION, ATTENUATES CHRONIC KIDNEY DISEASE PROGRESSION IN 5/6 NEPHRECTOMY MICE THROUGH REDUCTION OF GUT-DERIVED UREMIC TOXIN
    Tungsanga, Somkanya
    Leelahavanichkul, Asada
    Tungsanga, Kriang
    Tumwasorn, Somying
    Katavetin, Pisut
    NEPHROLOGY, 2021, 26 : 7 - 7
  • [50] Effect of soluble dietary fiber on gut microbiota and derived metabolites in stage 3 to 5 chronic kidney disease patients: A randomized controlled trial
    Cui, Yuan
    Kuang, Dingwei
    Wang, Jing
    Huo, Shaoye
    Li, Peng
    Lu, Lin
    Wei, Yuhuan
    Wang, Lihong
    Zhong, Xiaojing
    Zhao, Yunhua
    Niu, Jianying
    Wang, Weibing
    Shao, Chunhai
    JOURNAL OF FUNCTIONAL FOODS, 2024, 116
12345